Merus (MRUS) Competitors $52.60 -0.39 (-0.74%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MRUS vs. ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, BPMC, BBIO, and VRNAShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Merus vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Intra-Cellular Therapies (NASDAQ:ITCI) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment. Which has preferable earnings and valuation, ITCI or MRUS? Intra-Cellular Therapies has higher revenue and earnings than Merus. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64Merus$36.13M100.76-$215.33M-$4.08-12.89 Is ITCI or MRUS more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Merus' net margin of -506.73%. Intra-Cellular Therapies' return on equity of -9.93% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Merus -506.73%-35.99%-29.83% Do institutionals and insiders have more ownership in ITCI or MRUS? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 96.1% of Merus shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by insiders. Comparatively, 4.6% of Merus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, ITCI or MRUS? Intra-Cellular Therapies has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Does the media favor ITCI or MRUS? In the previous week, Merus had 7 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 7 mentions for Merus and 0 mentions for Intra-Cellular Therapies. Merus' average media sentiment score of 0.48 beat Intra-Cellular Therapies' score of 0.00 indicating that Merus is being referred to more favorably in the news media. Company Overall Sentiment Intra-Cellular Therapies Neutral Merus Neutral Do analysts recommend ITCI or MRUS? Intra-Cellular Therapies currently has a consensus price target of $109.70, suggesting a potential downside of 16.81%. Merus has a consensus price target of $84.64, suggesting a potential upside of 60.91%. Given Merus' stronger consensus rating and higher probable upside, analysts plainly believe Merus is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Merus 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.14 SummaryMerus beats Intra-Cellular Therapies on 11 of the 17 factors compared between the two stocks. Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.67B$2.84B$5.46B$8.90BDividend YieldN/A2.70%5.36%4.13%P/E Ratio-12.8921.1526.4419.67Price / Sales100.76259.51405.32110.29Price / CashN/A41.2925.8827.49Price / Book5.567.247.945.42Net Income-$215.33M-$55.05M$3.15B$248.34M7 Day Performance-2.83%-1.01%0.63%0.81%1 Month Performance-5.55%5.98%4.96%5.01%1 Year Performance-3.40%0.83%32.55%18.10% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus1.9458 of 5 stars$52.60-0.7%$84.64+60.9%-11.1%$3.67B$36.13M-12.8937ITCIIntra-Cellular Therapies0.9128 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9789 of 5 stars$20.68-2.3%$39.17+89.4%-17.8%$13.26B$3.12B11.752,682Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories2.8099 of 5 stars$15.31+0.5%$16.95+10.7%-1.4%$12.78B$3.81B23.2027,811ASNDAscendis Pharma A/S3.52 of 5 stars$175.78-0.6%$220.67+25.5%+26.6%$10.75B$393.54M-27.991,017VTRSViatris3.0162 of 5 stars$8.85-0.2%$10.40+17.5%-16.0%$10.39B$14.74B-2.7932,000QGENQiagen3.7171 of 5 stars$46.72-0.1%$47.74+2.2%+20.3%$10.39B$2.00B117.145,765Dividend AnnouncementMRNAModerna4.5255 of 5 stars$25.67-0.9%$46.61+81.6%-76.8%$9.93B$3.14B-2.945,800Trending NewsGap UpBPMCBlueprint Medicines1.7358 of 5 stars$128.40+0.2%$128.06-0.3%+18.9%$8.29B$508.82M-51.98640Positive NewsHigh Trading VolumeBBIOBridgeBio Pharma4.693 of 5 stars$42.17+1.1%$56.67+34.4%+70.5%$8.01B$127.42M-11.95400Analyst ForecastInsider TradeVRNAVerona Pharma PLC American Depositary Share1.6943 of 5 stars$97.05+2.9%$101.10+4.2%+554.1%$7.87B$118.54M-48.5330 Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Viatris Competitors Qiagen Competitors Moderna Competitors Blueprint Medicines Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRUS) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRUS Stock Alerts